| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1055-9965.EPI-07-0197 |
| P698 | PubMed publication ID | 17971519 |
| P50 | author | Endel John Orav | Q12362078 |
| Steven J Jacobsen | Q37384936 | ||
| Kinwei Chan | Q43184451 | ||
| Laurel A Habel | Q82880626 | ||
| Bette J. Caan | Q87148470 | ||
| Stephen K Van Den Eeden | Q87734385 | ||
| Reina Haque | Q88303669 | ||
| John D Seeger | Q91589185 | ||
| Rachel Whitmer | Q101012143 | ||
| Charles Quesenberry | Q102048181 | ||
| Barbara Sternfeld | Q110251076 | ||
| Virginia P Quinn | Q113440142 | ||
| Marianne C Sadler | Q114724020 | ||
| E Dawn Flick | Q114724031 | ||
| P433 | issue | 11 | |
| P921 | main subject | California | Q99 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | 2218-2225 | |
| P577 | publication date | 2007-10-30 | |
| P1433 | published in | Cancer Epidemiology, Biomarkers & Prevention | Q326334 |
| P1476 | title | Statin use and risk of prostate cancer in the California Men's Health Study cohort | |
| P478 | volume | 16 |
| Q33961730 | A new method for assessing how sensitivity and specificity of linkage studies affects estimation |
| Q90589091 | A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer |
| Q92060712 | Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells |
| Q35775751 | Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. |
| Q36075269 | Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study |
| Q36877126 | Association between plasma cholesterol and prostate cancer in the PSA era. |
| Q34418735 | Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort |
| Q37167232 | Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. |
| Q34415704 | Association of serum cholesterol and cholesterol-lowering drug use with serum sex steroid hormones in men in NHANES III. |
| Q24614649 | Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery |
| Q90603036 | Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study |
| Q88801267 | Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells |
| Q90576571 | Avoidable flaws in observational analyses: an application to statins and cancer |
| Q57307183 | Blood lipid levels and prostate cancer risk; a cohort study |
| Q33716515 | Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin |
| Q57140725 | Chemoprevention of prostate cancer |
| Q33732687 | Cholesterol and benign prostate disease |
| Q42079833 | Cholesterol and prostate cancer |
| Q37596358 | Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo |
| Q81407191 | Current awareness: pharmacoepidemiology and drug safety |
| Q42982919 | Effect of Statins on Serum Prostate-specific Antigen Levels |
| Q42424383 | Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity |
| Q38728309 | Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model |
| Q34028899 | Exposure to statins and risk of common cancers: a series of nested case-control studies |
| Q42045919 | Ezetimibe is an inhibitor of tumor angiogenesis |
| Q33826605 | Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo |
| Q34141720 | Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors |
| Q37694029 | Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib |
| Q35988999 | LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. |
| Q33882778 | Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial |
| Q33769607 | Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol |
| Q51156222 | Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study. |
| Q42956899 | Nutrients and risk of prostate cancer |
| Q39341924 | Prediction of malignancy in cystic neoplasms of the pancreas: a population-based cohort study |
| Q37794799 | Prevention Strategies in Prostate Cancer |
| Q35847370 | Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma |
| Q44804897 | Progression and treatment of incident lower urinary tract symptoms (LUTS) among men in the California Men's Health Study |
| Q92234762 | Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications |
| Q38802230 | Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? |
| Q37258845 | Rationale for statins in the chemoprevention of prostate cancer. |
| Q46892598 | Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients |
| Q36407365 | Serum total and HDL cholesterol and risk of prostate cancer |
| Q52603655 | Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia. |
| Q36195699 | Statin Use Reduces Prostate Cancer All-Cause Mortality: A Nationwide Population-Based Cohort Study |
| Q34003588 | Statin and NSAID use and prostate cancer risk |
| Q34433564 | Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. |
| Q35282895 | Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database |
| Q34021312 | Statin use and cancer risk: a comprehensive review |
| Q35038889 | Statin use and fatal prostate cancer: a matched case-control study |
| Q85995735 | Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study |
| Q36953616 | Statin use and prostate cancer risk in a large population-based setting |
| Q44904629 | Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. |
| Q21133952 | Statin use and risk of prostate cancer: a meta-analysis of observational studies |
| Q36978974 | Statin use and risk of prostate cancer: results from a population-based epidemiologic study |
| Q44560037 | Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies |
| Q89014477 | Statin use and time to progression in men on active surveillance for prostate cancer |
| Q39828211 | Statin use is associated with improved prostate cancer survival: is it time for a clinical trial? |
| Q88264960 | Statin use linked with a decrease in the conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer |
| Q36449867 | Statins and prostate cancer diagnosis and grade in a veterans population |
| Q37187362 | Statins and prostate cancer prevention: where we are now, and future directions. |
| Q27000727 | Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis |
| Q39666388 | Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. |
| Q28073619 | Targeting intratumoral androgens: statins and beyond |
| Q37205121 | The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey |
| Q34976557 | The association between statin use and the diagnosis of prostate cancer in a population based cohort |
| Q34590302 | The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer |
| Q35137013 | The complex interplay between cholesterol and prostate malignancy |
| Q38800777 | The current evidence on statin use and prostate cancer prevention: are we there yet? |
| Q26822900 | The failure of cancer chemoprevention |
| Q44840521 | The influence of statin medications on prostate-specific antigen levels |
| Q38151145 | The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review. |
| Q34328954 | The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network |
| Q37834362 | The role of randomized controlled trials in evidence-based urology |
| Q38175776 | The strategies to control prostate cancer by chemoprevention approaches |
Search more.